April was both National Minority Health Month and Counselling Awareness Month, designations that call attention to persistent health disparities among racial and ethnic minorities and lift
China's Luye Pharma has claimed its first FDA approval, getting a green light for Rykindo, an injectable formulation of the antipsychotic risperidone given every two weeks.
BioXcel Therapeutics has claimed its first product approval, getting a green light from the FDA for Igalmi as a treatment for agitation in people with schizophrenia or bipolar disorder.
The FDA approval of Alkermes' new antipsychotic drug Lybalvi couldn't have gone any better for the company, but it could still face a big challenge positioning the new drug in the highly ge
A sublingual film for acute agitation in schizophrenia and bipolar disorder from BioXcel has blockbuster potential that could pose a threat to an inhaled rival from Galen, according to anal
It has been five years since Lexicon Pharma's type 1 diabetes therapy, Zynquista, was rejected by the FDA, and it may struggle to have a better outcome at its second attempt.